H K Manji

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers
    H K Manji
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892, USA
    Mol Psychiatry 7:S46-56. 2002
  2. ncbi Riluzole in psychiatry: a systematic review of the literature
    Carlos A Zarate
    Mark O Hatfield CRC, Bethesda, Maryland 20892, USA
    Expert Opin Drug Metab Toxicol 4:1223-34. 2008
  3. ncbi Post-receptor signaling pathways in the pathophysiology and treatment of mood disorders
    H K Manji
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, 10 Center Drive, 10 4N 222 MSC 1381, Bethesda, MD, 20892, USA
    Curr Psychiatry Rep 2:479-89. 2000
  4. ncbi Signal transduction and genes-to-behaviors pathways in psychiatric diseases
    Husseini K Manji
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, NIMH, Bethesda, MD 20892, USA
    Sci STKE 2003:pe49. 2003
  5. ncbi Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics
    H K Manji
    Laboratory of Molecular Pathophysiology, NIMH, Building 49, Room B1EE16, 49 Convent Dr MSC 4405, Bethesda, MD 20892 4405, USA
    Psychopharmacol Bull 35:5-49. 2001
  6. ncbi Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilizers
    H K Manji
    Laboratory of Molecular Pathophysiology, Wayne State University School of Medicine, Detroit, Michigan, USA
    Br J Psychiatry Suppl 41:s107-19. 2001
  7. ncbi The cellular neurobiology of depression
    H K Manji
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland, USA
    Nat Med 7:541-7. 2001
  8. ncbi The nature of bipolar disorder
    H K Manji
    Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Mich, USA
    J Clin Psychiatry 61:42-57. 2000
  9. ncbi Neuroplasticity and cellular resilience in mood disorders
    H K Manji
    Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, USA
    Mol Psychiatry 5:578-93. 2000
  10. ncbi Valproate robustly enhances AP-1 mediated gene expression
    G Chen
    Laboratory of Molecular Pathophysiology, Department of Psychiatry and Behavioral Neurosciences, WSU School of Medicine, 2301 Scott Hall, 540 E Canfield Avenue, Detroit, MI 48201, USA
    Brain Res Mol Brain Res 64:52-8. 1999

Collaborators

Detail Information

Publications112 found, 100 shown here

  1. ncbi PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers
    H K Manji
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892, USA
    Mol Psychiatry 7:S46-56. 2002
    ....
  2. ncbi Riluzole in psychiatry: a systematic review of the literature
    Carlos A Zarate
    Mark O Hatfield CRC, Bethesda, Maryland 20892, USA
    Expert Opin Drug Metab Toxicol 4:1223-34. 2008
    ..Riluzole, a neuroprotective agent with anticonvulsant properties approved for the treatment of amyotrophic lateral sclerosis (ALS) is one such agent...
  3. ncbi Post-receptor signaling pathways in the pathophysiology and treatment of mood disorders
    H K Manji
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, 10 Center Drive, 10 4N 222 MSC 1381, Bethesda, MD, 20892, USA
    Curr Psychiatry Rep 2:479-89. 2000
    ....
  4. ncbi Signal transduction and genes-to-behaviors pathways in psychiatric diseases
    Husseini K Manji
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, NIMH, Bethesda, MD 20892, USA
    Sci STKE 2003:pe49. 2003
    ..It is likely that genetic findings in severe psychiatric disorders will continue to implicate direct and indirect modulation of critical intracellular signaling pathways...
  5. ncbi Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics
    H K Manji
    Laboratory of Molecular Pathophysiology, NIMH, Building 49, Room B1EE16, 49 Convent Dr MSC 4405, Bethesda, MD 20892 4405, USA
    Psychopharmacol Bull 35:5-49. 2001
    ..The future development of treatments that more directly target molecules involved in critical CNS cell survival and cell death pathways thus hold promise as novel, improved long-term treatments for mood disorders...
  6. ncbi Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilizers
    H K Manji
    Laboratory of Molecular Pathophysiology, Wayne State University School of Medicine, Detroit, Michigan, USA
    Br J Psychiatry Suppl 41:s107-19. 2001
    ..New research is dramatically altering our understanding of the molecular mechanisms underlying neuronal communication...
  7. ncbi The cellular neurobiology of depression
    H K Manji
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland, USA
    Nat Med 7:541-7. 2001
    ..Agents designed to directly target molecules in these pathways may hold promise as new therapeutics for depression...
  8. ncbi The nature of bipolar disorder
    H K Manji
    Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Mich, USA
    J Clin Psychiatry 61:42-57. 2000
    ....
  9. ncbi Neuroplasticity and cellular resilience in mood disorders
    H K Manji
    Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, USA
    Mol Psychiatry 5:578-93. 2000
    ....
  10. ncbi Valproate robustly enhances AP-1 mediated gene expression
    G Chen
    Laboratory of Molecular Pathophysiology, Department of Psychiatry and Behavioral Neurosciences, WSU School of Medicine, 2301 Scott Hall, 540 E Canfield Avenue, Detroit, MI 48201, USA
    Brain Res Mol Brain Res 64:52-8. 1999
    ....
  11. ncbi Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology
    J A Quiroz
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892, USA
    Mol Psychiatry 9:756-76. 2004
    ..While the task of developing novel medications for bipolar disorder is truly daunting, these and similar approaches will ultimately lead to better medications for the millions who suffer from this devastating illness...
  12. ncbi Molecular mechanisms underlying mood stabilization in manic-depressive illness: the phenotype challenge
    O C Ikonomov
    Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Am J Psychiatry 156:1506-14. 1999
    ..The authors critically examine the evidence supporting the hypothesis that lithium's therapeutic effects in bipolar affective disorder are mediated by alterations in the expression of specific genes in critical neuronal circuits...
  13. ncbi Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist
    Rodrigo Machado-Vieira
    Mood and Anxiety Disorders Program, Laboratory of Molecular Psychiatry and Experimental Therapeutics, National Institute of Mental Health NIMH, National Institutes of Health NIH, Department of Health and Human Services, Bethesda, Maryland, USA
    J Clin Psychiatry 70:1662-6. 2009
    ..This study investigated whether changes in brain-derived neurotrophic factor (BDNF) levels are associated with the initial antidepressant effects of ketamine, a high-affinity N-methyl-D-aspartate (NMDA) antagonist...
  14. ncbi Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness
    H K Manji
    Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Mich 48201, USA
    J Clin Psychiatry 61:82-96. 2000
    ....
  15. ncbi The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth
    P X Yuan
    Laboratory of Molecular Pathophysiology, Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    J Biol Chem 276:31674-83. 2001
    ..These data demonstrate that VPA is an ERK pathway activator and produces neurotrophic effects...
  16. ncbi Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression
    Husseini K Manji
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland 20892-4405, USA
    Biol Psychiatry 53:707-42. 2003
    ..The development of novel, nonaminergic-based therapeutics holds much promise for improved treatment of severe, refractory mood disorders...
  17. ncbi Pramipexole for bipolar II depression: a placebo-controlled proof of concept study
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institute of Health, Department of Human and Health Services, Bethesda, Maryland, USA
    Biol Psychiatry 56:54-60. 2004
    ..02). One subject on pramipexole and two on placebo developed hypomanic symptoms. CONCLUSIONS: The dopamine agonist pramipexole was found to have significant antidepressant effects in patients with bipolar II depression...
  18. ncbi The role of the extracellular signal-regulated kinase signaling pathway in mood modulation
    Haim Einat
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 4405, USA
    J Neurosci 23:7311-6. 2003
    ..These data suggest that the ERK pathway may mediate the antimanic effects of mood stabilizers...
  19. ncbi A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression
    Nancy Diazgranados
    Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Arch Gen Psychiatry 67:793-802. 2010
    ..Pharmacological strategies that produce rapid antidepressant effects-for instance, within a few hours or days-would have an enormous impact on patient care and public health...
  20. ncbi Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder
    Dara M Cannon
    Molecular Imaging Branch, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA
    Biol Psychiatry 62:870-7. 2007
    ....
  21. ncbi Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania
    G Shaltiel
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Mol Psychiatry 13:858-72. 2008
    ..The molecular mechanism underlying the behavioral effects of lithium in GluR6 KO mice remains to be elucidated...
  22. ncbi The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior
    Jing Du
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20878, USA
    J Neurosci 28:68-79. 2008
    ..These studies provide novel insights into the role of hippocampal GluR1/2 receptors in mediating facets of the manic syndrome and offer avenues for the development of novel therapeutics for these disorders...
  23. ncbi Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants
    O Malkesman
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Intramural Research Program, National Institutes of Health, Bethesda, MD, USA
    Mol Psychiatry 17:770-80. 2012
    ..Taken together, the results suggest that functional perturbation of apoptotic proteins such as Bid and, alternatively, enhancement of Bcl-2 function, is a putative strategy for developing novel therapeutics for mood disorders...
  24. ncbi Enhancement of hippocampal neurogenesis by lithium
    G Chen
    Laboratory of Molecular Pathophysiology, Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    J Neurochem 75:1729-34. 2000
    ..These results add to the growing body of evidence suggesting that mood stabilizers and antidepressants exert neurotrophic effects and may therefore be of use in the long-term treatment of other neuropsychiatric disorders...
  25. ncbi Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo
    G Chen
    Department of Psychiatry and Behavioral Neurosciences, WSU School of Medicine, Detroit, MI 48201, USA
    Bipolar Disord 2:217-36. 2000
    ..Together, these results suggest that the PKC signaling pathway and PKC-mediated gene expression may be important mediators of lithium's long-term therapeutic effects in a disorder as complex as BD...
  26. ncbi Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression
    Jing Du
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, Maryland 20892, USA
    J Neurosci 24:6578-89. 2004
    ....
  27. ncbi Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors
    Todd D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892 3711, USA
    Neuropsychopharmacology 32:2173-83. 2007
    ..By associating the behavioral effects of lithium with beta-catenin levels, these data suggest that increasing beta-catenin might be a novel therapeutic strategy for mood disorders...
  28. ncbi The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders
    Neil A Gray
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892, USA
    J Clin Psychiatry 64:3-17. 2003
    ....
  29. ncbi Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test
    Todd D Gould
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    Neuropharmacology 54:577-87. 2008
    ..Lithium may exert its antidepressant effects in humans through AMPA receptors, thus further supporting a role of targeting AMPA receptors as a therapeutic approach for the treatment of depression...
  30. ncbi Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine
    Giacomo Salvadore
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Biol Psychiatry 65:289-95. 2009
    ..We also investigated patterns of ACC activity to rapid presentation of fearful faces compared with the normal habituation observed in healthy subjects...
  31. ncbi Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist
    Laura E Phelps
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health DHHS, 10 Center Drive, Bethesda, MD 20892 1282, USA
    Biol Psychiatry 65:181-4. 2009
    ..This study investigated whether a family history of alcohol dependence influences ketamine's initial antidepressant effect...
  32. ncbi The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS
    G Chen
    Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    J Neurochem 72:879-82. 1999
    ..These novel findings represent the first report of medication-induced increases in CNS bcl-2 levels and may have implications not only for mood disorders, but also for long-term treatment of various neurodegenerative disorders...
  33. ncbi Signalling pathways in the brain: cellular transduction of mood stabilisation in the treatment of manic-depressive illness
    H K Manji
    Department of Psychiatry, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Aust N Z J Psychiatry 33:S65-83. 1999
    ....
  34. ncbi Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness
    G J Moore
    Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Am J Psychiatry 156:1902-8. 1999
    ..Lithium's effects on in vivo brain myo-inositol levels were investigated longitudinally in 12 adult depressed patients with manic-depressive illness...
  35. ncbi Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers
    Rulun Zhou
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Neuropsychopharmacology 34:1395-405. 2009
    ..These findings are the first to demonstrate that miRNAs and their predicted effectors are targets for the action of psychotherapeutic drugs...
  36. ncbi Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis
    Yanlei Hao
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892-4405, USA
    J Neurosci 24:6590-9. 2004
    ..This cascade of events provides a potential mechanism whereby mood stabilizers alleviate cerebral morphometric deficits associated with manic-depressive illness...
  37. ncbi AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test
    Todd D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892-3711, USA
    Int J Neuropsychopharmacol 7:387-90. 2004
    ....
  38. ncbi The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers
    Rulun Zhou
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland 20852, USA
    J Neurosci 25:4493-502. 2005
    ....
  39. ncbi Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors
    Sungho Maeng
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Biol Psychiatry 63:349-52. 2008
    ..Understanding the mechanisms underlying the intriguing effects of N-methyl d-aspartate (NMDA) antagonists could lead to novel treatments with a rapid onset of action...
  40. ncbi Lithium regulates total and synaptic expression of the AMPA glutamate receptor GluR2 in vitro and in vivo
    Neil A Gray
    National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA
    Ann N Y Acad Sci 1003:402-4. 2003
  41. ncbi Possible involvement of the ERK signaling cascade in bipolar disorder: behavioral leads from the study of mutant mice
    H Einat
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 4405, USA
    Drug News Perspect 16:453-63. 2003
    ....
  42. ncbi Lithium treatment in ovo: effects on embryonic heart rate, natural death of ciliary ganglion neurons, and brain expression of a highly conserved chicken homolog of human MTG8/ETO
    O C Ikonomov
    Laboratory of Molecular Pathophysiology, Department of Psychiatry and Behavioral Neurosciences, Wayne State University, School of Medicine, 4237 Scott Hall, 540 E Canfield, Detroit, MI 48201, USA
    Brain Res Dev Brain Res 123:13-24. 2000
    ..We propose that the induction of ETO expression, in concert with lithium-induced upregulation of other genes, such as PEBP2beta and bcl-2, is participating in the neuroprotective effect of chronic lithium treatment...
  43. ncbi The extracellular signal-regulated kinase pathway contributes to the control of behavioral excitement
    S R Engel
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892 3711, USA
    Mol Psychiatry 14:448-61. 2009
    ..Whether there is a shared mechanism through which mood stabilizers produce their clinical actions on mood, thought and behavioral symptoms of mania also requires further investigation...
  44. ncbi Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania
    Steven T Szabo
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Building 35, 1C912, Bethesda, MD 20892, USA
    Neuropharmacology 56:47-55. 2009
    ..These results suggest that PKC modulators or their intracellular targets may ultimately represent novel avenues for the development of new therapeutics for mood disorders...
  45. ncbi The anterior cingulate ERK pathway contributes to regulation of behavioral excitement and hedonic activity
    Thomas K Creson
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, NIH, Bethesda, MD 20892 3711, USA
    Bipolar Disord 11:339-50. 2009
    ..Here we investigated the extent to which perturbation of one of the affected pathways, the ERK pathway, in the ACC influences affective-related behavior...
  46. ncbi Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage
    Rosilla F Bachmann
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Neuropsychopharmacol 12:805-22. 2009
    ..These agents may have potential clinical utility in the treatment of other diseases associated with impaired mitochondrial function, such as neurodegenerative diseases and schizophrenia...
  47. ncbi A comparison of cognitive functioning in medicated and unmedicated subjects with bipolar depression
    M Kathleen Holmes
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Bipolar Disord 10:806-15. 2008
    ..The present study aims to compare the cognitive performance of medicated and unmedicated subjects with bipolar depression to healthy control subjects...
  48. ncbi The female urine sniffing test: a novel approach for assessing reward-seeking behavior in rodents
    Oz Malkesman
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Intramural Research Program, National Institutes of Health, Bethesda, Maryland 20892, USA
    Biol Psychiatry 67:864-71. 2010
    ..We describe a novel approach for monitoring reward-seeking behavior in rodents: sniffing of estrus female urine by male mice, along with number of ultrasonic vocalizations (USVs) emitted during the test...
  49. ncbi Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia
    Peixiong Yuan
    Biomarker Laboratory, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    J Affect Disord 124:164-9. 2010
    ..The extent of the possible involvement of this pathway in psychiatric disorders remains unknown, as does its potential utility as a pharmacological target for the future development of novel therapeutics...
  50. ncbi In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3
    Todd D Gould
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, MD 20892-4405, USA
    Neuropsychopharmacology 29:32-8. 2004
    ..These results strongly suggest that lithium significantly inhibits brain glycogen synthase kinase-3 in vivo at concentrations relevant for the treatment of bipolar disorder...
  51. ncbi Structurally dissimilar antimanic agents modulate synaptic plasticity by regulating AMPA glutamate receptor subunit GluR1 synaptic expression
    Jing Du
    Laboratory of Molecular Pathophysiology, National Institutes of Mental Health, National Institutes of Health, Bethesda, Maryland 20892-4405, USA
    Ann N Y Acad Sci 1003:378-80. 2003
    ....
  52. ncbi Kinases as drug targets in the treatment of bipolar disorder
    Lisa A Catapano
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, NIH, HHS, Bethesda, MD, USA
    Drug Discov Today 13:295-302. 2008
    ..This short review will focus on two of the most promising such targets: glycogen synthase-3 and protein kinase C...
  53. ncbi Generation and behavioral characterization of beta-catenin forebrain-specific conditional knock-out mice
    Todd D Gould
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    Behav Brain Res 189:117-25. 2008
    ..Alternatively, regulating beta-catenin may modulate drug effects rather than being a model of mood disorder pathophysiology per se...
  54. ncbi Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers
    T D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892, USA
    Mol Psychiatry 9:734-55. 2004
    ....
  55. ncbi High levels of Gs alpha in platelets of euthymic patients with bipolar affective disorder
    P B Mitchell
    Experimental Therapeutics Branch, NIMH, Bethesda, MD, USA
    Am J Psychiatry 154:218-23. 1997
    ..To determine whether such G protein abnormalities are a trait phenomenon, the authors investigated the levels of G protein alpha subunits in platelets and lymphocytes of euthymic patients with bipolar affective disorder...
  56. ncbi Translational research in bipolar disorder: emerging insights from genetically based models
    G Chen
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Mol Psychiatry 15:883-95. 2010
    ....
  57. ncbi Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A
    Mitchel A Kling
    Clinical Neuroendocrinology Branch, Division of Intramural Research Programs, National Institute of Mental Health, Bethesda, MD 20892 1284, USA
    Biol Psychiatry 62:309-13. 2007
    ..Elevations of the inflammatory markers C-reactive protein (CRP) and serum amyloid A (SAA) predict increased CAD risk in populations; few data on these markers exist in MDD, particularly in remitted patients...
  58. ncbi The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders
    Rodrigo Machado-Vieira
    Experimental Therapeutics, Mood and Anxiety Disorders Research Program, NIMH NIH, Bethesda, Maryland 20892, USA
    Neuroscientist 15:525-39. 2009
    ..In therapeutically relevant paradigms, ketamine preferentially targets postsynaptic AMPA/NMDA receptors, and riluzole preferentially targets presynaptic voltage-operated channels and glia...
  59. ncbi Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB
    Gonzalo Laje
    Unit on the Genetic Basis of Mood and Anxiety Disorders, National Institute of Mental Health, Bethesda, MD 20892 3719, USA
    Int J Neuropsychopharmacol 13:715-24. 2010
    ....
  60. ncbi In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked?
    De Maw Chuang
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892 1363, USA
    Biol Psychiatry 62:4-6. 2007
  61. ncbi The role of AMPA receptor modulation in the treatment of neuropsychiatric diseases
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health/NIH, 10 Center Drive, Bethesda, MD 20892, USA
    Exp Neurol 211:7-10. 2008
  62. ncbi Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Bipolar Disord 9:561-70. 2007
    ..In this study, we investigated whether antimanic effects can be achieved with a protein kinase C inhibitor in subjects with mania...
  63. ncbi Neurobiology of bipolar disorder
    Andrew R Newberg
    National Institute of Mental Health, 10 Center Drive, MSC 1282, Building 10 CRC, Room 7 5545, Bethesda, MD 20892 1282, USA
    Expert Rev Neurother 8:93-110. 2008
    ....
  64. ncbi The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis
    Rodrigo Machado-Vieira
    Experimental Therapeutics, Mood and Anxiety Disorders Research Program, NIMH NIH, Department of Health and Human Services, Bethesda, MD 20892, USA
    Bipolar Disord 11:92-109. 2009
    ..Continued work to decipher lithium's molecular actions will likely lead to the development of not only improved therapeutics for BD, but to neurotrophic enhancers that could prove useful in the treatment of many other illnesses...
  65. ncbi Abnormal hippocampal functioning and impaired spatial navigation in depressed individuals: evidence from whole-head magnetoencephalography
    Brian R Cornwell
    Mood and Anxiety Disorders Program, NIMH, 15K North Dr, MSC 2670, Bethesda, MD 20892, USA
    Am J Psychiatry 167:836-44. 2010
    ..The authors aimed to link spatial navigation deficits previously documented in depressed patients to abnormal hippocampal functioning using a virtual reality navigation task...
  66. ncbi Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium
    Todd D Gould
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, NIH, HHS, Bethesda, MD 20892 3711, USA
    Neuropsychopharmacology 32:1321-33. 2007
    ....
  67. ncbi Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders
    Todd D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, NIH, Bethesda, MD 20892 3711, USA
    Curr Drug Targets 7:1399-409. 2006
    ..The evidence described in this review suggests that regulating GSK-3 may represent a target for novel medications to treat mood disorders...
  68. ncbi Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms
    Alan G Mallinger
    Mood and Anxiety Disorders Program, National Institutes of Health Intramural Research Program, Building 10, Room 3N210, MSC 1290, Bethesda, MD 20892, USA
    Bipolar Disord 10:856-66. 2008
    ..Verapamil has shown antimanic activity in some but not all studies. Therefore, we investigated verapamil, used alone or as an adjunctive treatment, in manic patients who did not respond to an initial adequate trial of lithium...
  69. ncbi Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: the impact of medication
    Jonathan Savitz
    Section on Neuroimaging in Mood and Anxiety Disorders, NIH NIMH MAP, Bethesda, MD 20892, USA
    Neuroimage 49:2966-76. 2010
    ..Here we extend these results to the amygdala. We raise the possibility that neuroplastic changes in the amygdala associated with BD are moderated by some mood stabilizing medications...
  70. ncbi Glycogen synthase kinase-3: a target for novel bipolar disorder treatments
    Todd D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, NIH, Bethesda, MD 20892, USA
    J Clin Psychiatry 65:10-21. 2004
    ..We conclude with a discussion of the GSK-3 inhibitors furthest in development and the clinical trials that may emerge...
  71. ncbi An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland, USA
    Biol Psychiatry 57:430-2. 2005
    ..This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in bipolar depression...
  72. ncbi New approaches to modeling bipolar disorder
    Haim Einat
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland, US
    Psychopharmacol Bull 37:47-63. 2003
    ..These new models hold much promise in delineating the underlying pathophysiology of bipolar disorder and for the development of novel, improved therapeutics. Psychopharmacology Bulletin...
  73. ncbi Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, Maryland 20892, USA
    Ann N Y Acad Sci 1003:273-91. 2003
    ....
  74. ncbi Discovering endophenotypes for major depression
    Gregor Hasler
    Mood and Anxiety Disorders Program, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, USA
    Neuropsychopharmacology 29:1765-81. 2004
    ....
  75. ncbi Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets
    Paul J Carlson
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland 20892, USA
    NeuroRx 3:22-41. 2006
    ....
  76. ncbi An open-label trial of riluzole in patients with treatment-resistant major depression
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics and the Pathophysiology Branch, Mood and Anxiety Disorders Program, NIMH, Department of Health and Human Services, NIH, Bethesda, MD 20892, USA
    Am J Psychiatry 161:171-4. 2004
    ..This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression...
  77. ncbi Bcl-2 polymorphism influences gray matter volume in the ventral striatum in healthy humans
    Giacomo Salvadore
    Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA
    Biol Psychiatry 66:804-7. 2009
    ..We tested the hypothesis that this SNP would modulate gray matter (GM) volume in the limbic-cortical-striatal-pallidal-thalamic circuitry that plays major roles in mood regulation...
  78. ncbi Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Bethesda, Maryland, USA
    CNS Drugs 23:569-82. 2009
    ..The development of CNS-penetrant PKC inhibitors may have considerable benefit for this devastating illness...
  79. ncbi G protein-coupled receptors in major psychiatric disorders
    Lisa A Catapano
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, NIH, HHS, Bethesda, MD 20892, USA
    Biochim Biophys Acta 1768:976-93. 2007
    ..The future development of novel agents targeting GPCR signaling cascades remains an exciting prospect for patients refractory to existing therapeutics...
  80. ncbi Regional cerebral glucose metabolic abnormalities in bipolar II depression
    Linda Mah
    Section on Neuroimaging in Mood and Anxiety Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA
    Biol Psychiatry 61:765-75. 2007
    ..This study investigated whether cerebral metabolic abnormalities previously reported in unmedicated BD subjects are evident in depressed bipolar disorder type II (BD II) subjects receiving lithium or divalproex...
  81. ncbi The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders
    Jing Du
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Neuropsychopharmacology 32:793-802. 2007
    ....
  82. ncbi A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression
    Carlos A Zarate
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, MD 20892, USA
    Arch Gen Psychiatry 63:856-64. 2006
    ..Converging lines of evidence suggest the role of the glutamatergic system in the pathophysiology and treatment of mood disorders...
  83. ncbi Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography
    Dara M Cannon
    Mood and Anxiety Disorders Program, Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892 2670, USA
    Biol Psychiatry 60:207-17. 2006
    ..This study used PET and [(11)C]DASB, a radioligand that afforded higher sensitivity and specificity for the 5-HTT than previously available radioligands, to compare 5-HTT binding between BD and control subjects...
  84. ncbi The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers
    Guang Chen
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, National Institute of Health, Bethesda, Maryland 20892 3711, USA
    Curr Opin Psychiatry 19:313-23. 2006
    ....
  85. ncbi MicroRNAs in mental health: from biological underpinnings to potential therapies
    Joshua G Hunsberger
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, 9000 Rockville Pike, Building 35, 1C912, Bethesda, MD 20892, USA
    Neuromolecular Med 11:173-82. 2009
    ..Clearly, considerable research is required to better determine any therapeutic potential of targeting miRNAs; however, these agents may provide the next generation of effective therapies for psychiatric illnesses...
  86. ncbi Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, Bethesda, Maryland, USA
    Biol Psychiatry 59:1006-20. 2006
    ....
  87. ncbi Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention
    Dennis S Charney
    Mood and Anxiety Disorders Research Program, National Institute of Mental Health, 15K North Drive, Room 101, MSC 2670, Bethesda, MD 20892 2670, USA
    Sci STKE 2004:re5. 2004
    ....
  88. ncbi Environmental enrichment requires adult neurogenesis to facilitate the recovery from psychosocial stress
    R J Schloesser
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health NIMH, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Mol Psychiatry 15:1152-63. 2010
    ....
  89. ncbi Antidepressants, metabolites, and apparent drug resistance
    W Z Potter
    Section on Clinical Pharmacology, National Institute of Mental Health, Bethesda, MD 20892
    Clin Neuropharmacol 13:S45-53. 1990
    ..Finally, principles are deduced for identifying those cases in which metabolic considerations are most likely to be relevant to observed drug resistance...
  90. ncbi Molecular and cellular mechanisms underlying mood stabilization in bipolar disorder: implications for the development of improved therapeutics
    H K Manji
    Laboratory of Molecular Pathophysiology, NIMH, Bethesda, MD 20892-4405, USA
    Mol Psychiatry 7:S1-7. 2002
  91. ncbi Signal-transducing G proteins and antidepressant drugs: evidence for modulation of alpha subunit gene expression in rat brain
    K P Lesch
    Section of Neuropharmacology, National Institute of Mental Health, Bethesda, Maryland
    Biol Psychiatry 32:549-79. 1992
    ..The development of novel drugs with G proteins as primary targets remains an attractive prospect for the future...
  92. ncbi Increased anxiety-like behaviors and mitochondrial dysfunction in mice with targeted mutation of the Bcl-2 gene: further support for the involvement of mitochondrial function in anxiety disorders
    Haim Einat
    College of Pharmacy, Duluth, University of Minnesota, 376 Kirby Plaza, 1208 Kirby Drive, Duluth, MN 55812, USA
    Behav Brain Res 165:172-80. 2005
    ..Our study, therefore demonstrates that Bcl-2 may be a key factor in anxiety disorders and that its effects may possibly originate from its role in the mitochondria...
  93. ncbi Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs
    Todd D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892, USA
    Neuropsychopharmacology 30:1223-37. 2005
    ..In this regard, as is discussed, there is a major effort underway to develop novel, specific, GSK-3 inhibitors...
  94. ncbi Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice
    Todd D Gould
    Laboratory of Molecular Pathophysiology, National Institutes of Mental Health, 49 Convent Drive, Room B1EE16, Bethesda, MD 20892, USA
    Pharmacol Res 48:49-53. 2003
    ..These results are consistent with the available epidemiological evidence that long-term lithium therapy does not increase cancer morbidity or mortality, but rather is associated with reduced overall mortality in bipolar disorder...
  95. ncbi Timing is everything: does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation?
    Jennifer L Payne
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland 20892 1283, USA
    Biol Psychiatry 52:921-6. 2002
    ....
  96. ncbi Mood disorders: treatment-induced changes in brain neurochemistry and structure
    Debra A Glitz
    Neuropsychiatric Research Unit, Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, USA
    Semin Clin Neuropsychiatry 7:269-80. 2002
    ....
  97. ncbi The Wnt signaling pathway in bipolar disorder
    Todd D Gould
    Neuroscientist 8:497-511. 2002
    ..The future development of selective GSK-3beta inhibitors may have considerable utility not only for the treatment of bipolar disorder but also for a variety of classical neurodegenerative disorders...
  98. ncbi Getting balance: drugs for bipolar disorder share target
    Joseph T Coyle
    Nat Med 8:557-8. 2002
  99. ncbi Endophenotypes in bipolar disorder
    Robert H Lenox
    Neuropsychopharmacology Program, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Am J Med Genet 114:391-406. 2002
    ..Furthermore, lithium has been shown to regulate circadian cycles in diverse species, including humans, possibly through inhibition of glycogen synthase kinase 3-beta (GSK-3beta), a known target of lithium...
  100. ncbi Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics
    Rosilla F Bachmann
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD, USA
    Mol Neurobiol 32:173-202. 2005
    ..This article also discusses approaches to develop novel treatments specifically for bipolar disorder...
  101. ncbi A double-blind, placebo-controlled study of memantine in the treatment of major depression
    Carlos A Zarate
    Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Human Health Services, Bethesda, MD, USA
    Am J Psychiatry 163:153-5. 2006
    ..This study was designed to assess possible antidepressant effects of memantine, a selective N-methyl-D-aspartate (NMDA) receptor antagonist in humans...